Michael J. Spellberg, Ph.D.
Dr. Michael Spellberg is a registered patent agent with a significant background in cancer immunology and molecular biology. Prior to joining the firm, Dr. Spellberg served as a postdoctoral research fellow for Dr. Carl Novina at the Dana Farber Cancer Institute, where he used cutting-edge CRISPR technology in the development of tools to epigenetically modify cancer cells and immune cells as a novel therapy.
Dr. Spellberg received his Ph.D. at Brandeis University in the lab of Dr. Michael Marr. During this time, he identified a novel function of a transcription factor for its role in regulating the small RNA pathways and viral immunity. Dr. Spellberg also received the NIH Genetics Training Grant and the Brandeis Innovation Sprout Grant, awarded by the Technology Transfer office for the development of a patentable invention.
Dr. Spellberg’s teaching experience includes:
- Assistant Instructor, CSHL Protein Purification and Characterization Course, Cold Spring Harbor, NY
- Teaching Assistant, Biology Laboratory Course, Brandeis University
- U.S. Patent and Trademark Office
- American Association for the Advancement of Science (AAAS)
- Boston Patent Law Association (BPLA)
Xiong, T. Meister, G. Workman, R. Kato, N. Spellberg, M. Turker, F. Timp, W. Ostermeier, M. Novina, C. Targeted DNA methylation in human cells using engineered dCas9-mehtyltransferases. Scientific Reports. 2017. DOI: 10.1038/s41598-017-06757-0.
Spellberg, M. Marr, M. FOXO regulates RNA interference in Drosophila and protects from RNA virus infection. PNAS. 2015. DOI: 10.1073/pnas.1517124112.
- Olson, C. Donovan, M. Spellberg, M. Marr, M. The insulin receptor cellular IRES confers resistance to eIF4A inhibition. eLIFE, 2013. DOI: 10.7554/eLife.00542.001.
- Panelist, "Career Workshop," University of Massachusetts Medical School RNA Therapeutics Conference, June 27, 2018